These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 30030767)

  • 21. Biosimilar ESAs: a comparative review.
    Wilson P; Wood C
    J Ren Care; 2015 Mar; 41(1):53-61. PubMed ID: 25348203
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions.
    Bennett CL; Nagai S; Bennett AC; Hoque S; Nabhan C; Schoen MW; Hrushesky WJ; Luminari S; Ray P; Yarnold PR; Witherspoon B; Riente J; Bobolts L; Brusk J; Tombleson R; Knopf K; Fishman M; Yang YT; Carson KR; Djulbegovic B; Restaino J; Armitage JO; Sartor OA
    Oncologist; 2021 Aug; 26(8):e1418-e1426. PubMed ID: 33586299
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Erythropoietin-induced treatment costs in patients suffering from renal anemia - a comparison between biosimilar and originator drugs.
    Hörbrand F; Rottenkolber D; Fischaleck J; Hasford J
    Gesundheitswesen; 2014 Nov; 76(11):e79-84. PubMed ID: 24493578
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Retacrit®, Biosimilar of Epoetin Alfa, in Chemotherapy-Induced Anemia in Routine Practice: Impact of Iron Supplementation.
    Laribi K; Spaeth D; Scotte F; Ray-Coquard I
    Oncology; 2022; 100(10):519-528. PubMed ID: 35051930
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Is there a reason for concern or is it just hype? - A systematic literature review of the clinical consequences of switching from originator biologics to biosimilars.
    Inotai A; Prins CPJ; Csanádi M; Vitezic D; Codreanu C; Kaló Z
    Expert Opin Biol Ther; 2017 Aug; 17(8):915-926. PubMed ID: 28650704
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Real World Data on the Utilization Pattern and Safety Profile of Infliximab Originator Versus Biosimilars in Italy: A Multiregional Study.
    Scavone C; Sessa M; Clementi E; Corrao G; Leone R; Mugelli A; Rossi F; Spina E; Capuano A
    BioDrugs; 2018 Dec; 32(6):607-617. PubMed ID: 30341487
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characteristics and outcomes of rheumatoid arthritis patients who started biosimilar infliximab.
    Sung YK; Cho SK; Kim D; Won S; Choi CB; Bang SY; Hong SJ; Kim HA; Koh EM; Lee HS; Suh CH; Yoo DH; Bae SC
    Rheumatol Int; 2017 Jun; 37(6):1007-1014. PubMed ID: 28214924
    [TBL] [Abstract][Full Text] [Related]  

  • 28. History of Erythropoiesis-Stimulating Agents, the Development of Biosimilars, and the Future of Anemia Treatment in Nephrology.
    Kalantar-Zadeh K
    Am J Nephrol; 2017; 45(3):235-247. PubMed ID: 28142147
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epoetin alfa-epbx: a new entrant into a crowded market. a historical review of the role of erythropoietin stimulating agents and the development of the first epoetin biosimilar in the United States.
    Anand S; Al-Mondhiry J; Fischer K; Glaspy J
    Expert Rev Clin Pharmacol; 2021 Jan; 14(1):1-8. PubMed ID: 33307871
    [No Abstract]   [Full Text] [Related]  

  • 30. In Search of Predictors of Switching Between Erythropoiesis-Stimulating Agents in Clinical Practice: A Multi-Regional Cohort Study.
    Ingrasciotta Y; Belleudi V; Trotta F; Addis A; Fontana A; Chinellato A; Ientile V; Tari DU; Roberto G; Pastorello M; Scondotto S; Cananzi P; Traversa G; Davoli M; Rossi M; Trifirò G;
    BioDrugs; 2020 Feb; 34(1):55-64. PubMed ID: 31595485
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Longer-term outcomes of darbepoetin alfa versus epoetin alfa in patients with ESRD initiating hemodialysis: a quasi-experimental cohort study.
    Winkelmayer WC; Chang TI; Mitani AA; Wilhelm-Leen ER; Ding V; Chertow GM; Brookhart MA; Goldstein BA
    Am J Kidney Dis; 2015 Jul; 66(1):106-13. PubMed ID: 25943715
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacoutilization of epoetins in naïve patients with hematological malignancies in an unselected Italian population under clinical practice setting: a comparative analysis between originator and biosimilars.
    Perrone V; Saragoni S; Buda S; Broccoli A; Degli Esposti L
    Biologics; 2016; 10():157-165. PubMed ID: 27942203
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical effectiveness and safety of erythropoietin-stimulating agents for the treatment of low- and intermediate-1-risk myelodysplastic syndrome: a systematic literature review.
    Park S; Greenberg P; Yucel A; Farmer C; O'Neill F; De Oliveira Brandao C; Fenaux P
    Br J Haematol; 2019 Jan; 184(2):134-160. PubMed ID: 30549002
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Biosimilars].
    Krämer I
    Ther Umsch; 2011 Nov; 68(11):659-66. PubMed ID: 22045529
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and effectiveness of biosimilar of Rituximab CT-P10 in the treatment of cryoglobulinemic vasculitis: the MARBLe study (Mixed cryoglobulinemiA Rituximab BiosimiLar).
    Vacchi C; Visentini M; Gragnani L; Fraticelli P; Tavoni A; Filippini D; Saccardo F; Lauletta G; Colantuono S; Atzeni F; Pioltelli P; Manfredi A; Casato M; Zignego AL; Monti G; Pietrogrande M; Galli M; Sebastiani M
    Intern Emerg Med; 2021 Jan; 16(1):149-156. PubMed ID: 32524338
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Outcomes Following a Mandatory Nonmedical Switch From Adalimumab Originator to Adalimumab Biosimilars in Patients With Psoriasis.
    Loft N; Egeberg A; Rasmussen MK; Bryld LE; Nissen CV; Dam TN; Ajgeiy KK; Iversen L; Skov L
    JAMA Dermatol; 2021 Jun; 157(6):676-683. PubMed ID: 33825804
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety of Marketed Cancer Supportive Care Biosimilars in the US: A Disproportionality Analysis Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
    Tanni KA; Truong CB; Almahasis S; Qian J
    BioDrugs; 2021 Mar; 35(2):239-254. PubMed ID: 33439472
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Epoetin biosimilars in Europe: five years on.
    Mikhail A; Farouk M
    Adv Ther; 2013 Jan; 30(1):28-40. PubMed ID: 23242745
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dosing Penalty of Erythropoiesis-Stimulating Agents After Switching From Originator to Biosimilar Preparations in Stable Hemodialysis Patients.
    Minutolo R; Borzumati M; Sposini S; Abaterusso C; Carraro G; Santoboni A; Mura C; Filiberti O; Santoro D; Musacchio R; Imperiali P; Fiorini F; De Nicola L; Russo D
    Am J Kidney Dis; 2016 Jul; 68(1):170-2. PubMed ID: 26879099
    [No Abstract]   [Full Text] [Related]  

  • 40. Biosimilar Use Among 38 ASCO PracticeNET Practices, 2019-2021.
    Bourbeau B; Lyman GH; Lei XJ; Jones L; Rosenthal J; Kozlik MM; Oettel KR; Tinger A; Page R
    JCO Oncol Pract; 2023 Jul; 19(7):516-522. PubMed ID: 37084324
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.